MERIT MEDICAL SYSTEMS Business Summary

Merit Medical Systems Inc. (MMSI) operates as a leading global manufacturer and marketer of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures, specifically within cardiology, radiology, oncology, critical care, and endoscopy. The company’s revenue model is primarily transaction-based, driven by the sale of high-volume clinical consumables across its two reporting segments: Cardiovascular and Endoscopy. The Cardiovascular segment is further diversified into peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturing (OEM) services. Merit differentiates itself through a vertically integrated supply chain and a specialized focus on procedural accessories, such as inflation devices, catheters, and guide wires. In the competitive landscape, Merit contends with large-scale peers like Boston Scientific and Terumo Corporation, as well as mid-sized specialists such as Teleflex and AngioDynamics, positioning itself as a high-agility leader in niche procedural categories that require deep clinical specialization. Founded in 1987 by Fred P. Lampropoulos, Merit transitioned to a new leadership era in late 2025 with the appointment of Martha G. Aronson as President and CEO. Aronson’s pedigree includes executive leadership roles at Medtronic, Ecolab, and Hill-Rom, providing the company with seasoned expertise in global healthcare scaling. The current executive suite includes Raul Parra as Chief Financial Officer and Neil Peterson as Chief Operating Officer, both long-tenured leaders who have been instrumental in the company’s margin expansion initiatives. In January 2026, F. Ann Millner, Ed.D., was appointed Chair of the Board, succeeding the founder and bringing extensive governance experience from her roles in the Utah State Senate and higher education. The leadership team is rounded out by Adam Smith (Chief Commercial Officer) and John Hall (EVP of Global R&D), who oversee the company’s 'Continued Growth' strategy. Merit’s institutional stability is reinforced by significant equity positions held by major investment firms such as BlackRock, Vanguard, and T. Rowe Price.